The Lymphoma Hub, run by Scientific Education Support in partnership with the European Lymphoma Institute, has continued to provide news on clinical trials and drug updates, key literature, and congress coverage throughout Q3 of 2021.
The hub provided coverage for the 2021 Pan Pacific Lymphoma Conference in August. The main coverage was focused on the challenges in diagnosis and prognosis, current and emerging clinical treatment approaches, and their impact on the quality of life for patients with acute and chronic lymphoma.
Earlier in September, the Lymphoma Hub provided highlights from the European School of Hematology (ESH) conference, "How I manage CAR-T therapies and bispecific antibodies for my patients." We updated our audience on the advantages and disadvantages of bispecific antibodies versus cellular therapies, reported on clinical case studies, and addressed practical considerations and guidelines.
Another interesting event covered by the Lymphoma Hub in mid-September was the 9th annual meeting of the Society of Hematologic Oncology (SOHO2021). We brought updates on talks from eminent speakers and specialists with expertise in the spectrum of hematologic diseases. Emphasis was given on the cutting-edge advances and practical clinical applications for the latest therapeutic approaches in the field of lymphocytic malignancies.
Later in September, the Lymphoma Hub covered the XIX International Workshop on Chronic Lymphocytic Leukemia (CLL), focusing on the latest therapeutic agents and their impact on the recovery of patients with CLL.
Another featured event for September was the 4th Annual Meeting for International Academy for Clinical Hematology (IACH), where we notified our readers about state-of-the-art therapy in hematologic malignancies. This included coverage on topics for immune therapies, CAR T-cell therapies, allogeneic stem cell transplantation, treatment-related complications, and practical management.
Reviewing the Lymphoma Hub's activity, Mia Hill, IME Director at Scientific Education Support, said:
"This quarter has been an especially busy period for the Lymphoma Hub. We provided social coverage for key congresses, resulting in over half a million impressions and over 3,000 direct website users. By attending these congresses, we bring education to those who cannot attend and ensure that they are able to have sight of educational messages and vital updates in lymphoma. Activity such as this would not be possible without our supporters. We would like to take this opportunity to show our gratitude for our existing supporters-Bristol Myers Squibb, Incyte, Roche, ADC Therapeutics, Genentech, Novartis, Epizyme, Karyopharm Therapeutics, TG Therapeutics."
For more information on the Lymphoma Hub, please visit lymphomahub.com. For media enquiries or to explore collaboration opportunities, please contact firstname.lastname@example.org or Barry.Connolly@scientificeducationsupport.com.
NOTES TO EDITOR
Lymphoma is described as the development of neoplastic cellular growth-cancer-in the lymphatic system. Lymphomas are divided into two major categories: Hodgkin and non-Hodgkin lymphomas, where the latter is more common.
About the Lymphoma Hub
The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge of lymphoma and CLL through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
The Lymphoma Hub enables time-stretched HCPs to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies, the Lymphoma Hub supports HCPs worldwide.
The Lymphoma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
Lymphoma Hub supporters
Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.
Bristol Myers Squibb
If you are interested in becoming a Lymphoma Hub supporter, please contact email@example.com.
About Scientific Education Support (SES)
SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our 'Know' education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.
Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology, including the ALL Hub, AML Hub, GvHD Hub, MDS Hub, MPN Hub, and Multiple Myeloma Hub.
About The European Lymphoma Institute (ELI)
Lymphoma, the sixth cancer worldwide in terms of incidence, is a complex disease. The European Lymphoma Institute (ELI) regroups top European specialists in the field of lymphoma within a net dedicated to research, training, and education. To date, 13 European academic research groups have come together in an effort to define strategies to analyze and characterize this cancer, common diagnostic procedures, and therapeutic standards, as well as to facilitate clinical and fundamental research at the European level.
As a result of this collaborative work-truly unique in the world-together, we are helping to bring lymphoma research forward and guarantee equal access for all patients to the best possible care.
Distributed by https://pressat.co.uk/